These findings suggest that targeting CHK2, and probably CHK1, in combination with proteasome inhibition could be an innovative strategy to overcome chemoresistance in patients with DLBCL [38]. This evidence concerns the gene CHEK1 and diffuse large B-cell lymphoma.